Ghrelin may reduce radiation-induced mucositis and anorexia in head-neck cancer.
Body weight loss is common in cancer patients, and is often associated with poor prognosis, it greatly impairs quality of life (QOL). Radiation therapy (RT) is used in head and neck cancers (HNC) either as a primary treatment or as an adjuvant therapy to surgery. Patients with HNC are most susceptible to malnutrition especially due to anorexia, which is aggravated by RT. Multiple pro-inflammatory cytokines, such as interleukin-6 (IL-6), interleukin-1beta (IL-1beta), interferon (IFN)-gamma and tumor necrosis factor-alpha(TNF-alpha), have been all associated with the development of both anorexia and oral mucositis. Radiation-induced mucositis occurs in almost all patients, who are treated for HNC, it could also cause weight loss. Ghrelin is a novel 28-amino acid peptide, which up-regulates body weight through appetite control, increase food intake, down-regulate energy expenditure and induces adiposity. Furthermore, ghrelin inhibits pro-inflammatory cytokines such as IL-1alpha, IL-1beta, TNF-alpha which may cause oral mucositis and aneroxia, which are the results of weight loss. Thus weight loss during RT is an early indicator of nutritional decline, we propose that recombinant ghrelin used prophylactically could be useful as an appetite stimulant; and preventive of mucositis because of its anti-inflammatory effect, it might help patients maintain weight over the course of curative RT of the HNC and can improve specific aspects of QOL. This issue warrants further studies.
Guney
Yildiz
Y
Department of Radiation Oncology, Ankara University School of Medicine, Cebeci Hospital, Dikimevi, Ankara 06590, Turkey. yildiz_guney@yahoo.com
Ozel Turkcu
Ummuhani
U
Hicsonmez
Ayse
A
Nalca Andrieu
Meltem
M
Kurtman
Cengiz
C
D000855:Anorexia / Q000000981:diagnostic imaging* / Q000517:prevention & control; D001066:Appetite; D054439:Ghrelin; D006258:Head and Neck Neoplasms / Q000503:physiopathology / Q000532:radiotherapy*; D006801:Humans; D052016:Mucositis / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D036361:Peptide Hormones / Q000627:therapeutic use*; D011877:Radionuclide Imaging; D011878:Radiotherapy / Q000009:adverse effects*
D054439:Ghrelin; D036361:Peptide Hormones